Τίτλος:
BCL2L12 protein overexpression is associated with favorable outcome in diffuse large B-cell lymphoma patients in the rituximab era
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Δεν υπάρχει περίληψη
Συγγραφείς:
Papageorgiou, S.G.
Kontos, C.K.
Foukas, P.G.
Panopoulou, E.
Vasilatou, D.
Rapti, S.-M.
Gkontopoulos, K.
Bazani, E.
Panayiotides, I.G.
Dimitriadis, G.
Scorilas, A.
Pappa, V.
Περιοδικό:
Clinical Lymphoma Myeloma and Leukemia
Εκδότης:
Taylor and Francis Ltd.
Λέξεις-κλειδιά:
BCL2L12 protein; common acute lymphoblastic leukemia antigen; cyclophosphamide; doxorubicin; interferon regulatory factor 4; Ki 67 antigen; messenger RNA; mitoxantrone; prednisone; protein bcl 2; protein bcl 6; protein p53; rituximab; tumor marker; unclassified drug; vincristine; antineoplastic agent; BCL2L12 protein, human; muscle protein; pharmacological biomarker; protein bcl 2; rituximab; tumor marker, apoptosis; B lymphocyte; B lymphocyte differentiation; cancer combination chemotherapy; cancer immunotherapy; cancer survival; chromosome 19q; disease free survival; follow up; gene dosage; gene locus; genetic heterogeneity; germinal center; human; immunohistochemistry; International Prognostic Index; large cell lymphoma; Letter; long term survival; outcome assessment; overall survival; priority journal; protein expression; recurrence free survival; survival rate; treatment response; diffuse large B cell lymphoma; gene expression regulation; genetics; HL-60 cell line; metabolism; mortality; prognosis; survival analysis; treatment outcome; upregulation, Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Pharmacological; Biomarkers, Tumor; Gene Expression Regulation, Neoplastic; HL-60 Cells; Humans; Lymphoma, Large B-Cell, Diffuse; Muscle Proteins; Prognosis; Proto-Oncogene Proteins c-bcl-2; Rituximab; Survival Analysis; Treatment Outcome; Up-Regulation
DOI:
10.3109/10428194.2015.1126588
